Precursors  	Precursors  	 NNP	O
of  	of  	 IN	O
breast  	breast  	 JJ	O
cancer  	cancer  	 NN	O
It  	It  	 PRP	O
has  	has  	 VBZ	O
become  	become  	 VBN	O
apparent  	apparent  	 JJ	O
that  	that  	 IN	O
estrogen  	estrogen  	 JJ	B-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
ER 	ER 	 NNP	B-NP
)  	)  	 -RRB-	O
-  	-  	 CD	O
positive  	positive  	 JJ	O
and  	and  	 CC	O
-  	-  	 CD	O
negative  	negative  	 JJ	B-NP
breast  	breast  	 NN	I-NP
lesions  	lesions  	 NNS	I-NP
are  	are  	 VBP	O
completely  	completely  	 RB	O
distinct  	distinct  	 JJ	O
diseases 	diseases 	 NNS	O
.  	.  	 .	O
Precursors  	Precursors  	 NNP	O
of  	of  	 IN	O
low-grade  	low-grade  	 JJ	B-NP
breast  	breast  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
are  	are  	 VBP	O
low-grade  	low-grade  	 JJ	B-NP
premalignant  	premalignant  	 JJ	I-NP
lesions 	lesions 	 NNS	I-NP
,  	,  	 ,	O
usually  	usually  	 RB	O
ER  	ER  	 NNP	B-NP
and  	and  	 CC	O
progesterone  	progesterone  	 JJ	B-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
PR 	PR 	 NNP	B-NP
)  	)  	 -RRB-	O
positive  	positive  	 JJ	O
and  	and  	 CC	O
HER2  	HER2  	 CD	B-NP
negative 	negative 	 JJ	I-NP
.  	.  	 .	O
On  	On  	 IN	O
the  	the  	 DT	O
other  	other  	 JJ	O
hand 	hand 	 NN	O
,  	,  	 ,	O
precursors  	precursors  	 VBG	O
of  	of  	 IN	O
high-grade  	high-grade  	 JJ	O
breast  	breast  	 NN	O
cancer  	cancer  	 NN	O
are  	are  	 VBP	O
high-grade  	high-grade  	 JJ	O
premalignant  	premalignant  	 JJ	B-NP
lesions 	lesions 	 NNS	I-NP
,  	,  	 ,	O
usually  	usually  	 RB	O
ER  	ER  	 NNP	B-NP
and  	and  	 CC	O
PR  	PR  	 NNP	B-NP
negative  	negative  	 JJ	I-NP
and  	and  	 CC	O
HER2  	HER2  	 CD	B-NP
positive 	positive 	 JJ	I-NP
.  	.  	 .	O
Lobular  	Lobular  	 JJ	B-NP
neoplasia  	neoplasia  	 NNS	I-NP
( 	( 	 -LRB-	O
LN 	LN 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
ductal  	ductal  	 JJ	B-NP
carcinoma  	carcinoma  	 NN	I-NP
in  	in  	 IN	I-NP
situ  	situ  	 NNS	I-NP
( 	( 	 -LRB-	O
DCIS 	DCIS 	 NNP	B-NP
)  	)  	 -RRB-	O
are  	are  	 VBP	O
important  	important  	 JJ	O
from  	from  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
point  	point  	 NN	I-NP
of  	of  	 IN	O
view 	view 	 NN	O
.  	.  	 .	O
LN  	LN  	 NNP	B-NP
increases  	increases  	 VBZ	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
bilateral  	bilateral  	 JJ	B-NP
breast  	breast  	 NN	I-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
why  	why  	 WRB	O
the  	the  	 DT	O
recommendation  	recommendation  	 NN	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
LN  	LN  	 NNP	B-NP
is  	is  	 VBZ	O
very  	very  	 RB	O
different  	different  	 JJ	O
-   	-   	 NN	O
from  	from  	 IN	O
just  	just  	 RB	O
following  	following  	 RB	O
up  	up  	 RB	O
up  	up  	 RB	O
to  	to  	 TO	O
bilateral  	bilateral  	 JJ	B-NP
mastectomy 	mastectomy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
complete  	complete  	 JJ	O
surgical  	surgical  	 JJ	B-NP
excision  	excision  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
lesion  	lesion  	 NN	I-NP
with  	with  	 IN	O
negative  	negative  	 JJ	B-NP
margins  	margins  	 NNS	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
usual  	usual  	 JJ	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
DCIS 	DCIS 	 NNP	B-NP
.  	.  	 .	O
Several  	Several  	 JJ	O
big  	big  	 JJ	O
randomized  	randomized  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
showed  	showed  	 VBD	O
the  	the  	 DT	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
adjuvant  	adjuvant  	 JJ	B-NP
radiotherapy  	radiotherapy  	 NNS	I-NP
( 	( 	 -LRB-	O
RT 	RT 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Some  	Some  	 DT	O
of  	of  	 IN	O
them  	them  	 PRP	O
suppose  	suppose  	 VBP	O
that  	that  	 IN	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
group  	group  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
do  	do  	 VBP	O
not  	not  	 RB	O
need  	need  	 VB	O
adjuvant  	adjuvant  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
adjuvant  	adjuvant  	 JJ	B-NP
tamoxifen  	tamoxifen  	 NN	I-NP
is  	is  	 VBZ	O
clear  	clear  	 RB	O
only  	only  	 RB	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
ER  	ER  	 NNP	B-NP
positive  	positive  	 JJ	I-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
UK 	UK 	 NNP	B-NP
/  	/  	 NNP	O
ANZ  	ANZ  	 NNP	B-NP
study  	study  	 NN	I-NP
showed  	showed  	 VBD	O
the  	the  	 DT	O
benefit  	benefit  	 NN	O
of  	of  	 IN	O
tamoxifen  	tamoxifen  	 VBG	O
only  	only  	 RB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
without  	without  	 IN	O
RT 	RT 	 NNP	B-NP
.  	.  	 .	O
